News

Heres the Biggest Problem Ocugen Faces Right Now

Motley Fool · last updated
Ocugen (NASDAQ:OCGN) is a latecomer to the coronavirus vaccine race. But just this month, a new name has popped up on the vaccine horizon and that is Ocugen. My one concern though is Ocugen has this deal for co-commercialization in the U.S. — and thats where we now have enough vaccine ordered for this year. I think theres going to be a lot of competition in the U.S. right away. Unless the vaccine is a whole lot better than rivals, its really going to face some difficult competition.
View full article

here today, more tomorrow

We’ve launched briefing.center with a focus on the press and media.

And we’ve added Citizen Cartwright, a daily quick-read news summary by veteran Washington journalist Linda Cartwright. We’ve also created a new voting rights knowledge center for Citizen Cartwright subscribers. (You can sign up for a dedicated morning email at citizencartwright.com.)

You can sign up here for full access to press and media and Citizen Cartwright on briefing.center.

You can use briefing.center as the center of your information management, or just one of your tools. We’re happy to discuss your information needs.

Sign up